Summarized by Masters of Longevity from Frontiers - Health.
Cardiometabolic clinicians and curious readers will open a narrative review comparing cardiovascular and kidney outcome evidence for incretin-based therapies, focusing on GLP-1 receptor agonists and the newer dual GIP/GLP-1 agent.
Key Takeaways
- Several GLP-1 receptor agonists reduced major adverse cardiovascular events in large randomized trials.
- Semaglutide has the strongest dedicated evidence for slowing clinically meaningful chronic kidney disease progression.
- Tirzepatide markedly improves glycemic control and body weight but kidney outcome evidence is limited and secondary.
